Positive Study Ongoing Study Data from AMG 510 in Patients with Previous Treated KRAS G12C-Mutated Solid Tumors

Positive Study Ongoing Study Data from AMG 510 in Patients with Previous Treated KRAS G12C-Mutated Solid Tumors

Amgen (AMGN) announced new data from its ongoing Phase I clinical trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a first-in-class investigational oral therapy designed to selectively and irreversibly target the...

Pin It on Pinterest